

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: R. GOVINDARAJAN et al.

Application No.: 09/853,619

Group Art Unit: 1614

Filed: May 14, 2001

Examiner: J. D. Goldberg

For: COMPOSITIONS AND METHODS
FOR THE TREATMENT OF
COLORECTAL CANCER

Attorney Docket No.: 9516-021

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321(c)

Assistant Commissioner for Patents

Washington, D.C. 20231

01/08/2003 LWUNDIRI 00000042 161150 09853619

01 FC:1814 110.00 CH

Sir:

The Board of Trustees of the University of Arkansas and Celgene Corporation are the assignees of the entire right, title and interest in and to the above-identified application by virtue of an assignment from Rangaswamy Govindarajan and Andrew Zeitlin, which was recorded on September 20, 2001 at Reel 012193, Frame 0508. Celgene Corporation is also the assignee of the entire right, title and interest in and to U.S. Patent Application No. 09/853,617 by virtue of an assignment from Jerome B. Zeldis, Andrew Zeitlin and Sol Barber, which was recorded on September 21, 2001 at Reel 012193, Frame 0434.

Celgene Corporation hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of any patent granted on U.S. Patent Application No. 09/853,617, which was filed May 14, 2001, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patent granted on U.S. Patent Application No. 09/853,617.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patent



RECEIVED
JAN 09 2003
TECH CENTER 1600/2900


13

- granted on U.S. Patent Application No. 09/853,617 in the event that the patent granted on U.S. Patent Application No. 09/853,617 later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

A fee of approximately \$ 110.00 is believed to be due under 37 C.F.R. 120(d) for this terminal disclaimer. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Date: January 7, 2003


Max Bachrach 45,479
(Reg. No.)
PENNIE & EDMONDS LLP
1667 K Street N.W.
Washington, DC 20006
(202) 496-4400

For: Anthony M. Insogna (Reg. No. 35,203)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure